Erratum: Protection of synapses against Alzheimer's- Linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers (Proceedings of the National Academy of Sciences of the United States of America (2009) 106 (1971-1976) DOI:10.1073/pnas.0809158106);Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 6, 2009, Pages 1971-1976

  De Felice, Fernanda G ^a,b   Vieira, Marcelo N N ^b   Bomfim, Theresa R ^b   Decker, Helena ^b   Velasco, Pauline T ^a   Lambert, Mary P ^a   Viola, Kirsten L ^a   Zhao, Wei Qin ^a,c   Ferreira, Sergio T ^b   Klein, William L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Aging; Diabetes; Plasticity; Receptors; Therapeutics

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CASEIN KINASE II; ROSIGLITAZONE;

ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN TISSUE; NERVE CELL PLASTICITY; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL;

EID: 60549084867     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0902058106     Document Type: Erratum

References (51)

1. Gong Y, et al. (2003) Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100:10417-10422.
2. Mattson MP (2004) Pathways towards and away from Alzheimer's disease. Nature 430:631-639.
3. Scheibel ME, Lindsay RD, Tomiyasu U, Scheibel AB (1975) Progressive dendritic changes in aging human cortex. Exp Neurol 47392-47403.
4. Terry RD, et al. (1991) Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30:572-580.
5. Klein WL, Krafft GA, Finch CE (2001) Targeting small A beta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24:219-224.
6. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298:789-791.
7. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101-112.
8. Ferreira ST, Vieira MN, De Felice FG (2007) Soluble protein oligomers as emerging toxins in Alzheimer's and other amyloid diseases. IUBMB Life 59:332-345.
9. Zhao WQ, et al. (2008) Amyloid beta oligomers induce impairment of neuronal insulin receptors. FASEB J 22:246-260.
10. Klein WL, Stine WB, Jr, Teplow DB (2004) Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol Aging 25:569-580.
11. Lambert MP, et al. (1998) Diffusible, nonfibrillar ligands derived from A beta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453.
12. Lacor PN, et al. (2004) Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 24:10191-10200.
13. Walsh DM, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416:535-539.
14. Selkoe DJ (2008) Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res 192:106-113.
15. De Felice FG, et al. (2008) Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol Aging 29:1334-1347.
16. De Felice FG, et al. (2007) A beta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 282:11590-11601.
17. Roselli F, et al. (2005) Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci 25:11061-11070.
18. Lacor PN, et al. (2007) A beta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27:796-807.
19. Shankar GM, et al. (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27:2866-2875.
20. Snyder EM, et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8:1051-1058.
21. Hsieh H, et al. (2006) AMPAR removal underlies A beta-induced synaptic depression and dendritic spine loss. Neuron 52:831-843.
22. Georganopoulou DG, et al. (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 102:2273-2276.
23. Lesné S, et al. (2006) A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-357.
24. Klyubin I, et al. (2005) Amyloid beta protein immunotherapy neutralizes A beta oligomers that disrupt synaptic plasticity in vivo. Nat Med 11:556-561.
25. Relkin NR, et al. (2008) 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging [Epub ahead of print]
26. Zhao W, et al. (1999) Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J Biol Chem 274:34893-34902.
27. Zhao WQ, Alkon DL (2001) Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 177:125-134.
28. Watson GS, et al. (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13:950-958.
29. Pedersen WA, et al. (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199:265-273.
30. Reger MA, et al. (2008) Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70:440-448.
31. Craft S (2007) Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res 4:147-152.
32. Ho L, et al. (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18:902-904.
33. Cao D, Lu H, Lewis TL, Li L (2007) Intake of sucrose-sweetened water induces insulin resistance and exacerbates memory deficits and amyloidosis in a transgenic mouse model of Alzheimer disease. J Biol Chem 282:36275-36282.
34. Crump FT, Dillman KS, Craig AM (2001) cAMP-dependent protein kinase mediates activity-regulated synaptic targeting of NMDA receptors. J Neurosci 21:5079-5088.
35. Boyer C, Schikorski T, Stevens CF (1998) Comparison of hippocampal dendritic spines in culture and in brain. J Neurosci 18:5294-5300.
36. Cole GM, Frautschy SA (2007) The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease. Exp Gerontol 42:10-21.
37. Clodfelder-Miller BJ, Zmijewska AA, Johnson GV, Jope RS (2006) Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 55:3320-3325.
38. Grünblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101:757-770.
39. Chung HJ, Huang YH, Lau LF, Huganir RL (2004) Regulation of the NMDA receptor complex and trafficking by activity-dependent phosphorylation of the NR2B subunit PDZ ligand. i24:10248-10259.
40. Benedict C, et al. (2007b) Intranasal insulin improves memory in humans: superiority of insulin aspart. Neuropsychopharmacology 32:239-243.
41. Townsend M, Mehta T, Selkoe DJ (2007) Soluble A beta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem 282:33305-33312.
42. Lee CC, Kuo YM, Huang CC, Hsu KS (2007) Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. Neurobiol Aging. [Epub ahead of print]
43. Risner ME, et al. (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6:246-254.
44. Lambert MP, et al. (2007) Monoclonal antibodies that target pathological assemblies of A beta. J Neurochem 100:23-35.
45. Skeberdis VA, Lan J, Zheng X, Zukin RS, Bennett MV (2001) Insulin promotes rapid delivery of N-methyl-D- aspartate receptors to the cell surface by exocytosis. Proc Natl Acad Sci USA 98:3561-3566.
46. Huang CC, You JL, Lee CC, Hsu KS (2003) Insulin induces a novel form of postsynaptic mossy fiber long-term depression in the hippocampus. Mol Cell Neurosci 24:831-841.
47. Gispen WH, Biessels GJ (2000) Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 23:542-549.
48. Spillantini MG, Goedert M (2008) Tau protein pathology in neurodegenerative diseases. Trends Neurosci 21:428-433.
49. Moloney AM, et al. (2008) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging. [Epub ahead of print]
50. Landreth G (2007) Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Curr Alzheimer Res 4:159-164.
51. Ryan CM, et al. (2006) Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 29:345-351.